ARTICLE | Company News

Lab21, Medical University of South Carolina deal

September 6, 2010 7:00 AM UTC

The university granted Lab21 an exclusive, worldwide license to IP covering the detection and analysis of genetic variants of the human carboxylesterase 1 ( CES1; hCE1) gene. Lab21 plans to offer CES1 analysis through its CLIA-certified and CPA-certified laboratories in the U.S. and Europe, respectively, to determine a patient's metabolism of specific drugs, including ADHD drug Ritalin methylphenidate and influenza drug Tamiflu oseltamivir. Lab21 will also develop diagnostic kits for pathology laboratories. Financial terms were not disclosed. ...